Keros Therapeutics, Inc. Share Price & Technical Analysis
KROS · $11.19 (-0.27%)
Healthcare / Biotechnology
$11.19
-0.27%
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
1% return in May, -4% avg return in past 3 year May month.
-53% return in 2026, 5% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -12% | -21% | -21% | 0% | 1% | – | – | – | – | – | – | – | -53% |
| 25 | -28% | 0% | -10% | 43% | -2% | -5% | 8% | 6% | 3% | -4% | 16% | 17% | 43% |
| 24 | 42% | 20% | -2% | -15% | -17% | -4% | 11% | -9% | 28% | -1% | -1% | -73% | -21% |
| 23 | 21% | -9% | -20% | 3% | 8% | -16% | 4% | -16% | -9% | -11% | 5% | 31% | -7% |
| 22 | -21% | 16% | 2% | -2% | -36% | -19% | 17% | 11% | 7% | 31% | -2% | -5% | -2% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$225.09M
P/E ratio
4.95
52W high
$22.55
52W low
$9.79
Volume
2,71,062
Beta
0.95
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Keros Therapeutics, Inc. share price today?
- Keros Therapeutics, Inc. (KROS) last traded around $11.19 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does KROS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for KROS. Download the app for real-time alerts.
- How can I analyze Keros Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.